Lineage Cell Therapeutics Inc at Noble Capital Markets Investor Conference (Virtual) Transcript
All right. Well, thank you, everyone. I appreciate Noble giving me the opportunity to conclude today's sessions; I will aim to make this one very memorable for you. Speaking of memorable, I know all of us in this room are old enough to remember, let's say, 20 years ago, when there was a lot of excitement about something called cell therapy, and it promised all sorts of wonderful and amazing things, new medicines, et cetera, et cetera. There were many scientists that were touting this new era; I was one of them, in fact. And I've got good news and bad news.
The bad news, of course, is that 20 years have gone by, and, with the exception of cancer, cell therapy hasn't really produced a lot of the things that it was promising to produce. However, the good news is it's finally starting to happen. And you can measure this in certain ways. You can measure this in the development of products, but you can also measure it on the capital side. And because this is an investment conference, you can point to things like the $1 billion acquisition of BlueRock
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
